Related references
Note: Only part of the references are listed.Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology
Stacey A. Cohen et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 20, 2019 (2019)
Active surveillance for low risk prostate cancer among men with high risk genetic predisposition
D. Halstuch et al.
EUROPEAN UROLOGY SUPPLEMENTS (2019)
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
Piper Nicolosi et al.
JAMA ONCOLOGY (2019)
Germline and Somatic Mutations in Prostate Cancer for the Clinician
Heather H. Cheng et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Association of BRCA1-and BRCA2-deficiency with mutation burden, expression of PD-L1/ PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
Wei Xiong Wen et al.
PLOS ONE (2019)
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
H. Ballentine Carter et al.
EUROPEAN UROLOGY (2019)
Male BRCA mutation carriers: clinical characteristics and cancer spectrum
Mohammed Ibrahim et al.
BMC CANCER (2018)
Genomic Markers in Prostate Cancer Decision Making
Vito Cucchiara et al.
EUROPEAN UROLOGY (2018)
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer
Yishuo Wu et al.
PROSTATE (2018)
Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
Sanghamitra Mylavarapu et al.
FRONTIERS IN ONCOLOGY (2018)
Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up.
Julie Nicole Graff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Men with a susceptibility to prostate cancer and the role of genetic based screening
Rosalind Eeles et al.
TRANSLATIONAL ANDROLOGY AND UROLOGY (2018)
Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer
Emmanuel S. Antonarakis
EUROPEAN UROLOGY (2017)
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer
Matti Annala et al.
EUROPEAN UROLOGY (2017)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
Julie Lecarpentier et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Heather H. Cheng et al.
EUROPEAN UROLOGY (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling
Heather H. Cheng et al.
PROSTATE (2016)
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
Michael T. Schweizer et al.
ONCOTARGET (2016)
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Elena Castro et al.
EUROPEAN UROLOGY (2015)
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Charlene Kan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2015)
Loss-of-function variants in ATM confer risk of gastric cancer
Hannes Helgason et al.
NATURE GENETICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
Maha Hussain et al.
INVESTIGATIONAL NEW DRUGS (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Colin C. Pritchard et al.
NATURE COMMUNICATIONS (2014)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study
N. Kentepozidis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Germline Mutations in HOXB13 and Prostate-Cancer Risk
Charles M. Ewing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
A recurrent mutation in PALB2 in Finnish cancer families
Hannele Erkko et al.
NATURE (2007)
Distinct functions of BRCA1 and BRCA2 in double-strand break repair
YL Liu et al.
BREAST CANCER RESEARCH (2002)
Share Paper
